Last update 23 Jan 2025

Al Health Eye Medicine (Liaoning) Co., Ltd.

Private Company|
2012|
Liaoning Sheng, China

Overview

Tags

Eye Diseases
Nervous System Diseases
Other Diseases
Fusion protein
Bispecific antibody
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Endocrinology and Metabolic Disease1
Hemic and Lymphatic Diseases1
Immune System Diseases1
Neoplasms1
Top 5 Drug TypeCount
Bispecific antibody1
Small molecule drug1
Fusion protein1
Top 5 TargetCount
C3 x C51
mAChRs(Muscarinic acetylcholine receptor)1

Related

3
Drugs associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
Atropine Sulfate
Target
mAChRs
Mechanism
mAChRs antagonists
Active Org.
Bausch & Lomb, Inc.Bausch & Lomb, Inc. [+37]
Originator Org.
Santen Pharmaceutical Co., Ltd.Santen Pharmaceutical Co., Ltd.
Active Indication
Myopia [+11]
Inactive Indication
Organophosphate Poisoning
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date20 Jul 1968
LP-005
Target
C3 x C5
Mechanism
C3 inhibitors [+1]
Active Org.
Tianchen Biomedical (Suzhou) Co., Ltd.Tianchen Biomedical (Suzhou) Co., Ltd. [+1]
Originator Org.
Al Health Eye Medicine (Liaoning) Co., Ltd. [+1]
Active Indication
Hemoglobinuria, Paroxysmal [+9]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
RX-001
Target
Complement system proteins
Mechanism
Complement system proteins inhibitors
Active Org.-
Originator Org.
Tianchen Biomedical (Suzhou) Co., Ltd.Tianchen Biomedical (Suzhou) Co., Ltd.
Active Indication-
Inactive Indication
Dystrophy, Macular
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
CTR20222723
/ CompletedPhase 1
评估低浓度硫酸阿托品滴眼液在中国健康成年受试者中单/多次给药的安全性、耐受性和药代动力学特征的I期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of single/multiple administrations of low-concentration atropine sulfate eye drops in healthy Chinese adult subjects
100 Clinical Results associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
Login to view more data
100 Deals associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Al Health Eye Medicine (Liaoning) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Phase 1 Clinical
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Atropine Sulfate
 ( mAChRs )		Myopia
More
Phase 1
LP-005
 ( C3 x C5 )		Dystrophy, Macular
More
Preclinical
RX-001
 ( Complement system proteins )		Dystrophy, Macular
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free